Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

This study tests a new type of CAR-T cell therapy (where a patient's own immune cells are engineered to attack disease) that targets two proteins — CD19 and BCMA — for treating severe, treatment-resistant autoimmune diseases such as lupus, myositis, and systemic sclerosis. CAR-T therapy has shown promise in autoimmune diseases where the immune system is attacking the body itself. **You may be eligible if...** - You are 18 to 70 years old - You have a severe autoimmune disease (such as systemic lupus erythematosus, inflammatory myopathy, or systemic sclerosis) that has not responded to standard treatments - Your organ function (blood counts, liver, kidneys, heart) meets the required levels **You may NOT be eligible if...** - You have active serious infections (HIV, active hepatitis B/C) - You have significant heart failure or other major organ failure - You are pregnant or breastfeeding - You have active cancer (other than the condition being treated) Talk to your doctor to see if this trial is right for you.